Clinical Therapeutics
Volume 34, Issue 1 , Pages 1-13 , January 2012

Fidaxomicin: The Newest Addition to the Armamentarium Against Clostridium difficile Infections

  • Jason W. Lancaster, PharmD, BCPS

      Affiliations

    • Corresponding Author InformationAddress correspondence to: Jason W. Lancaster, PharmD, BCPS, Department of Pharmacy Practice, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, 360 Huntington Avenue, 206 Mugar Life Sciences Building, Boston, MA, 02115
    • ,
  • S. James Matthews, RPh, PharmD

,Accepted 9 December 2011.

References 

  1. Dificid [package insert] . San Diego, Calif: Optimer Pharmaceutics; 2011;
  2. Hubert B , Loo VG , Bourgault AM , et al.  A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Quebec . Clin Infect Dis . 2007;44:238–244
  3. Kuijper EJ , Coignard B , Tull P . Emergence of Clostridium difficile-associated disease in North America and Europe . Clin Microbiol Infect . 2006;12(Suppl 6):2–18
  4. Loo VG , Poirier L , Miller MA , et al.  A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality . N Engl J Med . 2005;353:2442–2449
  5. McDonald LC , Owings M , Jernigan DB . Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003 . Emerg Infect Dis . 2006;12:409–415
  6. Muto CA , Pokrywka M , Shutt K , et al.  A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use . Infect Control Hosp Epidemiol . 2005;26:273–280
  7. Kuijper EJ , Barbut F , Brazier JS , et al.  Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008 . Euro Surveill . 2008;13:1–7
  8. Gerding DN . Disease associated with Clostridium difficile infection . Ann Intern Med . 1989;110:255–257
  9. Lyerly DM , Krivan HC , Wilkins TD . Clostridium difficile: its disease and toxins . Clin Microbiol Rev . 1988;1:1–18
  10. McFarland LV , Stamm WE . Review of Clostridium difficile-associated diseases . Am J Infect Control . 1986;14:99–109
  11. Grundfest-Broniatowski S , Quader M , Alexander F , et al.  Clostridium difficile colitis in the critically ill . Dis Colon Rectum . 1996;39:619–623
  12. Kyne L , Merry C , O'Connell B , et al.  Factors associated with prolonged symptoms and severe disease due to Clostridium difficile . Age Ageing . 1999;28:107–113
  13. Lawrence SJ , Puzniak LA , Shadel BN , et al.  Clostridium difficile in the intensive care unit: epidemiology, costs, and colonization pressure . Infect Control Hosp Epidemiol . 2007;28:123–130
  14. Kyne L , Hamel MB , Polavaram R , et al.  Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile . Clin Infect Dis . 2002;34:346–353
  15. Ackermann G , Thomalla S , Ackermann F , et al.  Prevalence and characteristics of bacteria and host factors in an outbreak situation of antibiotic-associated diarrhoea . J Med Microbiol . 2005;54:149–153
  16. Bartlett JG . Clostridium difficile: history of its role as an enteric pathogen and the current state of knowledge about the organism . Clin Infect Dis . 1994;18(Suppl 4):S265–S272
  17. Zilberberg MD . Clostridium difficile-related hospitalizations among US adults, 2006 . Emerg Infect Dis . 2009;15:122–124
  18. O'Brien JA , Lahue BJ , Caro JJ , et al.  The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences . Infect Control Hosp Epidemiol . 2007;28:1219–1227
  19. McDonald LC , Killgore GE , Thompson A , et al.  An epidemic, toxin gene-variant strain of Clostridium difficile . N Engl J Med . 2005;353:2433–2441
  20. Goncalves C , Decre D , Barbut F , et al.  Prevalence and characterization of a binary toxin (actin-specific adp-ribosyltransferase) from Clostridium difficile . J Clin Microbiol . 2004;42:1933–1939
  21. Warny M , Pepin J , Fang A , et al.  Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe . Lancet . 2005;366:1079–1084
  22. Gravel D , Miller M , Simor A , et al.  Health care-associated clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian nosocomial infection surveillance program study . Clin Infect Dis . 2009;48:568–576
  23. Cohen SH , Gerding DN , Johnson S , et al.  Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) . Infect Control Hosp Epidemiol . 2010;31:431–455
  24. Vancocin [package insert] . Exton, Pa: ViroPharma, Inc; 2005;
  25. Pepin J , Valiquette L , Alary ME , et al.  Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity . CMAJ . 2004;171:466–472
  26. Zar FA , Bakkanagari SR , Moorthi KM , et al.  A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity . Clin Infect Dis . 2007;45:302–307
  27. Louie T., Gerson M., Grimard D., et al. Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in Clostridium difficile-Associated Diarrhea (CDAD). Abstract presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17–20, 2007; Chicago, Ill.
  28. Baines SD , O'Connor R , Freeman J , et al.  Emergence of reduced susceptibility to metronidazole in Clostridium difficile . J Antimicrob Chemother . 2008;62:1046–1052
  29. Al-Nassir WN , Sethi AK , Li Y , et al.  Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease . Antimicrob Agents Chemother . 2008;52:2403–2406
  30. Sethi AK , Al-Nassir WN , Nerandzic MM , et al.  Skin and environmental contamination with vancomycin-resistant enterococci in patients receiving oral metronidazole or oral vancomycin treatment for Clostridium difficile-associated disease . Infect Control Hosp Epidemiol . 2009;30:13–17
  31. Johnson AP . New antibiotics for selective treatment of gastrointestinal infection caused by Clostridium difficile . Expert Opin Ther Pat . 2010;20:1389–1399
  32. Berman AL . Efficacy of rifaximin and vancomycin combination therapy in a patient with refractory Clostridium difficile-associated diarrhea . J Clin Gastroenterol . 2007;41:932–933
  33. Herpers BL , Vlaminckx B , Burkhardt O , et al.  Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection . Clin Infect Dis . 2009;48:1732–1735
  34. Johnson S , Schriever C , Galang M , et al.  Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin . Clin Infect Dis . 2007;44:846–848
  35. Juang P , Skledar SJ , Zgheib NK , et al.  Clinical outcomes of intravenous immune globulin in severe Clostridium difficile-associated diarrhea . Am J Infect Control . 2007;35:131–137
  36. McFarland LV , Elmer GW , Surawicz CM . Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease . Am J Gastroenterol . 2002;97:1769–1775
  37. Musher DM , Logan N , Mehendiratta V , et al.  Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide . J Antimicrob Chemother . 2007;59:705–710
  38. Pepin J , Routhier S , Gagnon S , et al.  Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada . Clin Infect Dis . 2006;42:758–764
  39. Coronelli C , White RJ , Lancini GC , et al.  Lipiarmycin, a new antibiotic from actinoplanes (Isolation, chemical, biological and biochemical characterization) . J Antibiot . 1975;28:253–259
  40. Parenti F , Pagani H , Beretta G . Lipiarmycin, a new antibiotic from actinoplanes (Description of the producer strain and fermentation studies) . J Antibiot . 1975;28:247–252
  41. Sergio S , Pirali G , White R , et al.  Lipiarmycin, a new antibiotic from actinoplanes (Mechanism of Action) . J Antibiot . 1975;28:543–549
  42. Gualtieri M , Villain-Guillot P , Latouche J , et al.  Mutation in the bacillus subtilis RNA polymerase beta' subunit confers resistance to lipiarmycin . Antimicrob Agents Chemother . 2006;50:401–402
  43. Osburne MS , Sonenshein AL . Inhibition by lipiarmycin of bacteriophage growth in Bacillus subtilis . J Virol . 1980;33:945–953
  44. Ackermann G , Loffler B , Adler D , et al.  In vitro activity of OPT-80 against Clostridium difficile . Antimicrob Agents Chemother . 2004;48:2280–2282
  45. Babakhani F , Gomez A , Robert N , et al.  Postantibiotic effect of fidaxomicin and its major metabolite (OP-1118) against Clostridium difficile . Antimicrob Agents Chemother . 2011;55:4427–4429
  46. Babakhani F., Robert N., Shangle S., et al. Antimicrobial activity and post-antibiotic effect (PAE) of OPT-80, a new macrocyclic compound, against Clostridium difficile. Abstract presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 29 -November 2, 2004; Washington, DC.
  47. Babakhani F., Seddon J., Robert N., et al. Narrow spectrum activity and low fecal protein binding of OPT-80 and its major hydrolysis metabolite (OP-1118). Abstract presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2007; Chicago, Ill.
  48. Citron DM , Babakhani F , Goldstein EJC , et al.  Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection . Anaerobe . 2009;15:234–236
  49. Credito KL , Appelbaum PC . Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species . Antimicrob Agents Chemother . 2004;48:4430–4434
  50. Finegold SM , Molitoris D , Vaisanen ML , et al.  In vitro activities of OPT-80 and comparator drugs against intestinal bacteria . Antimicrob Agents Chemother . 2004;48:4898–4902
  51. Hecht DW , Galang MA , Sambol SP , et al.  In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004 . Antimicrob Agents Chemother . 2007;51:2716–2719
  52. Karlowsky J.A., Laing N.M., Alfa M., et al. In vitro antimicrobial activities of OPT-80, rifaximin, tigecycline, and comparators against toxin-positive Clostridium difficile cultured from diarrheal stool specimens. Abstract presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17- 20, 2007; Chicago, Ill.
  53. Babakhani F , Gomez A , Robert N , et al.  Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile . J Med Microbiol . 2011;60:1213–1217
  54. Biedenbach DJ , Ross JE , Putnam SD , et al.  In vitro activity of fidaxomicin (OPT-80) tested against contemporary clinical isolates of Staphylococcus spp. and Enterococcus spp . Antimicrob Agents Chemother . 2010;54:2273–2275
  55. Louie TJ , Emery J , Krulicki  , et al.  OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C (difficile infection) . Antimicrob Agents Chemother . 2009;53:261–263
  56. Nerandzic M.M., Mullane K.M., Miller M.A., et al. Acquisition and overgrowth of vancomycin-resistant enterococci in patients treated with either fidaxomicin (FDX) or vancomycin (VAN) for Clostridium difficile infection. Abstract presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12-15, 2009; San Francisco, Calif.
  57. Babakhani F., Shangle S., Robert N., et al. Resistance development, crossresistance, and synergy studies of OPT-80. Abstract presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 29-November 2, 2004; Washington, DC.
  58. Miller M., Mastrantonio P., Blanchette R., et al. Rifampin, rifaximin, OPT-80 and tigecycline susceptibility of C. difficile strains from Canada and Italy. Abstract presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12-15, 2009; San Francisco, Calif.
  59. Swanson RN , Hardy DJ , Shipkowitz NL , et al.  In vitro and in vivo evaluation of tiacumicins b and c against Clostridium difficile . Antimicrob Agents Chemother . 1991;35:1108–1111
  60. Shue YK , Sears PS , Shangle S , et al.  Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses . Antimicrob Agents Chemother . 2008;52:1391–1395
  61. Louie T , Miller M , Donskey C , et al.  Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection . Antimicrob Agents Chemother . 2009;53:223–228
  62. Louie T., Miller M., Crook D., et al. Effect of advancing age on outcomes of therapy for Clostridium difficile infection. Abstract presented at: Annual Scientific Meeting of the American Geriatrics Society; May 11-14, 2011; Washington, DC.
  63. Crook D., Weiss K., Cornely O.A., et al. Randomized clinical trial in Clostridium difficile infection confirms equivalent cure rate and lower recurrence rate of fidaxomicin versus vancomycin. Abstract presented at: 20th European Congress of Clinical Microbiology and Infectious Diseases, April 10-13, 2010; Vienna, Austria.
  64. Mullane K., Golan Y., Crook D., et al. Renal impairment and response to fidaxomicin versus vancomycin in patients with clostridium difficile infection. Abstract presented at: 49th Annual meeting of the Infectious Diseases Society of America; October 20-23, 2011; Boston, Mass.
  65. Louie TJ , Miller MA , Mullane KM , et al.  Fidaxomicin versus vancomycin for Clostridium difficile infection . N Engl J Med . 2011;364:422–431
  66. Cheknis A.K., Citron D.M., Nagaro K.J., et al. Epidemic BI/NAP1 is the dominant strain of Clostridium difficile found in patients in the OPT-80 vs. Vancomycin clinical trial in North American and the European Union. Abstract presented at: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 25-28, 2008; Washington, DC.
  67. Golan Y., Mullane K.M., Miller M.A., et al. Low recurrence rate among patients with C. difficile infection (CDI) treated with fidaxomicin (FDX). Abstract presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12-15, 2009; San Francisco, Calif.
  68. Gorbach S., Weiss K., Sears P., et al. Safety of fidaxomicin versus vancomycin in treatment of Clostridium difficile infection. Abstract presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12-15, 2009; San Francisco, Calif.
  69. Goldstein EJ , Citron DM , Sears P , et al.  Comparative susceptibilities of fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two fidaxomicin phase III trials of Clostridium difficile infection . Antimicrob Agents Chemother . 2011;55:5194–5199
  70. Mullane KM , Miller MA , Weiss K , et al.  Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections . Clin Infect Dis . 2011;53:440–447
  71. Okumu F., Walsh R.B., Sears P., et al. Safety and pharmacokinetics of OPT- 80, a novel antibiotic for treatment of Clostridium difficile associated diarrhea (CDAD). Abstract presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 29-November 2, 2004; Washington, DC.
  72. Drug Topics Red Book . Montvale, NJ: Thompson Medical Economics; 2011;

PII: S0149-2918(11)00838-1

doi: 10.1016/j.clinthera.2011.12.003

Clinical Therapeutics
Volume 34, Issue 1 , Pages 1-13 , January 2012

Article Tools

* Image Usage & Resolution